Thymulin
Thymulin is a zinc-dependent nonapeptide hormone (also called the serum thymic factor, FTS) produced by thymic epithelial cells, whose biological activity requires zinc binding, and human evidence largely concerns endogenous thymulin/zinc status rather than trials of administered thymulin peptide itself.
This page is a research-orientation summary, not a dosing guide. For anything beyond general background, read the primary literature or talk to a qualified clinician — specifics like amount, frequency, or administration aren't something we publish here.
What it does & how it works
Thymulin is secreted by thymic epithelial cells and only becomes biologically active when bound to zinc (forming Zn-FTS); the zinc-free form (FTS) is inactive. In its active zinc-bound state, thymulin promotes T-lymphocyte differentiation and modulates cell-mediated immune responses, making circulating zinc bioavailability a key rate-limiting regulator of thymulin's biological activity in vivo.
Typical results seen in research
Human studies are largely observational/correlational and focus on endogenous thymulin and zinc status rather than exogenous peptide administration: patients with beta-thalassemia major show reduced plasma zinc and active thymulin levels alongside altered lymphocyte subsets; in advanced HIV infection, active (zinc-bound) thymulin is markedly reduced and correlates with CD4+ cell depletion, and zinc supplementation in one study restored active thymulin levels and was associated with fewer recurrent opportunistic infections. Analogous zinc-thymulin-immune relationships have been shown in animal (piglet) models of zinc deficiency. Because these studies mostly examine zinc's effect on endogenous thymulin activity rather than injecting synthetic thymulin, they should not be read as direct evidence for exogenous thymulin peptide therapy.
How it’s commonly used
Thymulin is most often studied as a blood biomarker of zinc-dependent thymic/immune status in human research; synthetic thymulin itself has been administered by injection only in limited experimental research settings rather than in established clinical protocols.
- Acta Haematologica · 2001 Immunological evaluation of patients with beta-thalassemia major
- Journal of Nutrition · 2000 Therapeutic application of zinc in human immunodeficiency virus against opportunistic infections
- Veterinary Immunology and Immunopathology · 1998 Zinc, thymic endocrine activity and mitogen responsiveness (PHA) in piglets exposed to maternal aflatoxicosis B1 and G1
Curated from published literature for research orientation. Not an exhaustive review, and not a substitute for reading primary sources.